You just read:

Aralez Announces FDA Approval Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers

News provided by

Aralez Pharmaceuticals Inc.

15 Sep, 2016, 09:33 ET